Effect of recombinant human brain natriuretic peptide on the cardiac function and serum N terminal pro-B-type natriuretic peptide level in elderly patients with heart failure
10.3760/cma.j.issn.1008-6706.2019.09.012
- VernacularTitle: 重组人脑利钠肽治疗高龄心力衰竭患者的疗效观察及其对血清N端B型钠尿肽原水平的影响
- Author:
Tianjing SONG
1
;
Yuquan WU
;
Hong LI
;
Xiaona CHEN
Author Information
1. Cadre Ward, the 117th Hospital of the Chinese People′s Liberation Army, Hangzhou, Zhejiang 310012, China
- Publication Type:Journal Article
- Keywords:
Heart failure;
Natriuretic peptide, brain;
Heart function tests;
Aged;
Comparative effectiveness research
- From:
Chinese Journal of Primary Medicine and Pharmacy
2019;26(9):1070-1073
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the effect of recombinant human brain natriuretic peptide (rhBNP) on the cardiac function and serum N terminal pro-B-type natriuretic peptide (NT-proBNP) level in elderly patients with heart failure.
Methods:From January 2015 to December 2017, 150 elderly patients (aged 80 years) with heart failure in the 117th Hospital of the Chinese People′s Liberation Army were selected in the research.According to the digital random list method, the patients were divided into two groups, with 75 cases in each group.The control group was given nitroglycerin treatment, and the observation group was given rhBNP treatment.The levels of serum NT-proBNP, left ventricular ejection fraction (LVEF), clinical efficacy and complications were compared between the two groups.
Results:After treatment, the levels of serum NT-proBNP in the two groups were significantly lower than before treatment, and the level of NT-proBNP in the observation group [(2 964.42±607.25)pg/mL] was significantly lower than that in the control group [(4 213.57±524.07)pg/mL] (t=13.49, P<0.01). After treatment, the levels of LVEF in the two groups were significantly higher than those before treatment, and the level of LVEF in the observation group [(51.26±4.77)%] was significantly higher than that in the control group [(46.03±5.22)%] (t=6.41, P<0.01). The total effective rate of the observation group was 94.67%(71/75), which was significantly higher than 70.67%(53/75) of the control group (χ2=13.45, P<0.01). There was no statistically significant difference in the incidence rate of complications such as headache, blood pressure drop, renal function deterioration and tachycardia etc.in the two groups (P>0.05).
Conclusion:rhBNP in the treatment of elderly patients with heart failure can effectively improve the symptoms of dyspnea and systemic symptoms, reduce serum NT-proBNP levels, improve heart function, and will not cause serious complications, with good safety, so it is worthy of clinical promotion and application.
